We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-1.26%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$7.91B
AUM Growth
-$2.56B
Cap. Flow
+$5.6B
Cap. Flow %
70.85%
Top 10 Hldgs %
34.65%
Holding
156
New
13
Increased
15
Reduced
59
Closed
23

Top Buys

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$7.7B
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$114M
3
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$76.7M
4
FOLD
Amicus Therapeutics
FOLD
+$76.6M
5
SCPH
scPharmaceuticals
SCPH
+$48.1M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$172M
2
AET
Aetna Inc
AET
+$163M
3
BIIB icon
Biogen
BIIB
+$128M
4
MRK icon
Merck
MRK
+$108M
5
GILD icon
Gilead Sciences
GILD
+$107M

Sector Composition

Rank Sector Weight
1 Healthcare 91.1%
2 Financials 1.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIIB icon
1
Biogen
BIIB
$30.4B
$392M 4.96%
1,230,700
-399,300
-24% -$128M
ALXN
2
DELISTED
Alexion Pharmaceuticals
ALXN
$344M 4.36%
2,879,575
-765,911
-21% -$93.3M
REGN icon
3
Regeneron Pharmaceuticals
REGN
$72.9B
$321M 4.06%
854,600
+281,830
+49% +$114M
CELG
4
DELISTED
Celgene Corp
CELG
$320M 4.04%
3,062,850
-289,127
-9% -$32.6M
VRTX icon
5
Vertex Pharmaceuticals
VRTX
$124B
$261M 3.3%
1,741,300
-333,002
-16% -$49.3M
BSX icon
6
Boston Scientific
BSX
$68.5B
$257M 3.26%
10,386,600
-3,010,400
-22% -$83M
AMGN icon
7
Amgen
AMGN
$212B
$226M 2.85%
1,297,100
+44,000
+4% +$7.79M
PBYI icon
8
Puma Biotechnology
PBYI
$406M
$216M 2.73%
2,184,535
-241,200
-10% -$27M
MRK icon
9
Merck
MRK
$326B
$204M 2.58%
3,799,419
-1,950,957
-34% -$108M
CMTA
10
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$198M 2.5%
10,425,225
– –
CI icon
11
Cigna
CI
$79.6B
$197M 2.49%
969,300
-296,800
-23% -$59.1M
LLY icon
12
Eli Lilly
LLY
$1.09T
$193M 2.44%
2,288,000
-787,000
-26% -$67M
A icon
13
Agilent Technologies
A
$39.7B
$173M 2.19%
2,590,700
-1,048,200
-29% -$70.7M
WMGI
14
DELISTED
Wright Medical Group Inc
WMGI
$152M 1.92%
6,852,068
-2,094,166
-23% -$51.6M
ELV icon
15
Elevance Health
ELV
$83.7B
$148M 1.87%
658,718
-268,900
-29% -$57.3M
IMMU
16
DELISTED
Immunomedics Inc
IMMU
$137M 1.73%
8,461,727
-1,535,089
-15% -$18.1M
ASND icon
17
Ascendis Pharma A/S
ASND
$16.7B
$135M 1.71%
3,367,315
– –
CLVS
18
DELISTED
Clovis Oncology, Inc.
CLVS
$134M 1.7%
1,971,670
-417,000
-17% -$29.2M
BOLD
19
DELISTED
Audentes Therapeutics, Inc
BOLD
$129M 1.63%
4,129,638
– –
EW icon
20
Edwards Lifesciences
EW
$48.2B
$127M 1.6%
3,372,300
-799,800
-19% -$29.4M
ALNY icon
21
Alnylam Pharmaceuticals
ALNY
$38.5B
$120M 1.51%
941,600
-143,200
-13% -$18M
ONC
22
BeOne Medicines Ltd
ONC
$34.3B
$102M 1.29%
1,041,488
-272,300
-21% -$24.9M
ABBV icon
23
AbbVie
ABBV
$465B
$102M 1.29%
1,050,600
-914,400
-47% -$86.2M
ARRY
24
DELISTED
Array Biopharma Inc
ARRY
$97.6M 1.23%
7,621,400
-6,561,500
-46% -$74.6M
SEM
25
DELISTED
Select Medical
SEM
$89.6M 1.13%
9,417,715
-935,981
-9% -$8.94M
1
2 3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q4 2017 Portfolio in Review

As of Q4 2017, OrbiMed held 156 positions worth $7.91B, down 24% from $10.5B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

OrbiMed deployed $5.6B of net new capital in Q4 2017, opening 13 new positions and adding to 15 existing holdings. Its largest new stake was Rhythm Pharmaceuticals: 2,901,295 shares worth $43.5M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 91% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Aetna Inc, an estimated $163M trimmed.

  • OrbiMed's largest Q4 2017 buy was Rhythm Pharmaceuticals: 2,901,295 shares worth $43.5M.
  • OrbiMed added most to Loxo Oncology, Inc in Q4 2017, an estimated $7.7B increase.
  • OrbiMed's biggest Q4 2017 reduction was Aetna Inc, cutting an estimated $163M.
  • OrbiMed fully exited Incyte in Q4 2017, selling an estimated $172M.
  • OrbiMed's ten largest holdings make up 35% of its $7.91B portfolio in Q4 2017.
  • OrbiMed opened 13 new positions and closed 23 in Q4 2017.
  • OrbiMed's portfolio value fell 24% quarter-over-quarter to $7.91B.

Based on OrbiMed's 13F filing for Q4 2017, filed 14 Feb 2018.